Cyclooxygenase-2 expression in chronic hepatitis C and the effect of interferon alpha treatment

J Gastroenterol Hepatol. 2007 Oct;22(10):1633-7. doi: 10.1111/j.1440-1746.2007.04869.x.

Abstract

Background and aim: Cyclooxygenase-2 (COX-2), a target of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs), is upregulated in chronic hepatitis B and may have a role in hepatocellular carcinoma. Little is known about the expression of COX-2 in chronic hepatitis C (HCV) infection. The aim the present study was to evaluate the extent of COX-2 expression in liver biopsies in patients with HCV infection and to determine the effect of treatment with interferon alpha (IFN).

Methods: Percutaneous liver biopsy specimens were retrieved. Following formalin fixation and paraffin embedding, the biopsies were histologically evaluated for inflammation and fibrosis. The extent of COX-2 expression was measured by the avidin biotin immunohistochemical technique using a monoclonal COX-2 antibody. The extent of COX-2 expression was graded according to the number of hepatocytes expressing COX-2. Data were analyzed using Student's t-test.

Results: Liver biopsies from 10 patients before and after treatment with IFN were obtained and compared with nine normal liver biopsies. All of the liver biopsies showed some COX-2 expression. COX-2 expression was confined to hepatocytes and bile duct epithelium and was not detected in vascular endothelium or inflammatory cells. The extent of COX-2 expression was greater in hepatitis C infected liver biopsies than in normal biopsies. Following treatment with IFN, there was a greater than threefold reduction in COX-2 expression (P < 0.01). This result was independent of the sustained virological response.

Conclusion: In this small pilot study we have shown that COX-2 is overexpressed in liver biopsies infected with HCV and COX-2 expression is reduced following treatment with IFN.

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Biopsy
  • Cyclooxygenase 2 / metabolism*
  • Female
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / enzymology*
  • Humans
  • Immunoenzyme Techniques
  • Interferon-alpha / therapeutic use*
  • Male
  • Middle Aged
  • Pilot Projects
  • Treatment Outcome
  • Up-Regulation

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Cyclooxygenase 2